Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK.
Nat Commun
; 14(1): 2799, 2023 05 16.
Article
Dans Anglais
| MEDLINE | ID: covidwho-2327022
ABSTRACT
Following primary SARS-CoV-2 vaccination, whether boosters or breakthrough infections provide greater protection against SARS-CoV-2 infection is incompletely understood. Here we investigated SARS-CoV-2 antibody correlates of protection against new Omicron BA.4/5 (re-)infections and anti-spike IgG antibody trajectories after a third/booster vaccination or breakthrough infection following second vaccination in 154,149 adults ≥18 y from the United Kingdom general population. Higher antibody levels were associated with increased protection against Omicron BA.4/5 infection and breakthrough infections were associated with higher levels of protection at any given antibody level than boosters. Breakthrough infections generated similar antibody levels to boosters, and the subsequent antibody declines were slightly slower than after boosters. Together our findings show breakthrough infection provides longer-lasting protection against further infections than booster vaccinations. Our findings, considered alongside the risks of severe infection and long-term consequences of infection, have important implications for vaccine policy.
Texte intégral:
Disponible
Collection:
Bases de données internationales
Base de données:
MEDLINE
Sujet Principal:
COVID-19
/
Type d'étude:
Étude observationnelle
/
Étude pronostique
Les sujets:
Vaccins
/
Variantes
Limites du sujet:
Adulte
/
Humains
Pays comme sujet:
Europe
langue:
Anglais
Revue:
Nat Commun
Thème du journal:
Biologie
/
Science
Année:
2023
Type de document:
Article
Pays d'affiliation:
S41467-023-38275-1
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS